Busulfan Immunoassay Antibodies Specific Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring busulfan levels in patients undergoing chemotherapy are labor-intensive and expensive, and existing immunoassays lack specificity, leading to variable therapeutic outcomes due to cross-reactivity with metabolites, which complicates the management of busulfan dosages and increases side effects.
Innovation Solution
Development of a new class of antibodies specifically reactive to busulfan with minimal cross-reactivity to its metabolites, such as tetramethylene sulfone and tetrahydrothiophene-3-ol-1,1-dioxide, using immunogens conjugated with polyamine polymers, enabling the creation of an immunoassay for precise detection and quantification of busulfan in biological fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gas chromatography/mass spectrometry is used for busulfan testing, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent replaces the complex mechanical and chemical GC/MS system with a biological immunoassay system using antibodies to detect busulfan levels. This substitution maintains measurement precision while dramatically simplifying the testing equipment and reducing operational complexity.
Solution Approach 2:
The patent introduces antibodies as intermediary substances that specifically bind to busulfan, enabling detection through immunological reactions rather than direct chemical analysis. This intermediary approach simplifies the measurement system while maintaining accuracy.
2Ease of operation
If existing immunoassays are used for busulfan monitoring, then ease of operation is improved, but measurement precision deteriorates due to cross-reactivity with metabolites
Solution Approach 1:
The patent applies local quality by designing antibodies with highly specific binding characteristics that distinguish busulfan from its metabolites. The antibodies are engineered to recognize specific molecular structures of busulfan while ignoring similar metabolites, achieving both ease of operation and measurement precision.
Solution Approach 2:
The patent changes the binding parameters of the antibody-reagent by using specially engineered antibodies with optimized affinity and specificity for busulfan. This parameter optimization ensures high precision detection while maintaining the simplicity of immunoassay operation.
3Ease of manufacture
If equal doses of busulfan are administered to different patients, then ease of manufacture is improved, but reliability deteriorates due to pharmacokinetic variability
Solution Approach 1:
The patent implements feedback by using the simplified immunoassay to monitor busulfan levels in individual patients and adjusting dosages accordingly. This feedback loop compensates for pharmacokinetic variability, ensuring reliable therapeutic outcomes while maintaining ease of drug administration.
Solution Approach 2:
The patent introduces dynamics by enabling flexible, individualized dosage adjustments based on real-time monitoring results. Rather than fixed dosages, the system allows dynamic modification of treatment protocols to match each patient's specific pharmacokinetic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new antibodies allow for accurate monitoring and adjustment of busulfan treatment, reducing side effects and improving therapeutic outcomes by providing a simple, automated, and specific immunoassay for busulfan levels, thereby enhancing individualized drug management.
Implementation Method 1
a new class of antibodies have been produced which are substantially selectively reactive to busulfan so as to bind to busulfan without any substantial cross reactivity to busulfan metabolites
Data Source
AI summary
Novel conjugates of busulfan and novel busulfan immunogens derived from α-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.